FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis

NORTH CHICAGO, Ill., April 23, 2019 /PRNewswire/ — AbbVie today announced that the U.S. Food and Drug Administration (FDA) approved Skyrizi (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe plaque…Original Article